Showing 34,667 results

People & personal stories

Instagram's Aids memorial: ‘History does not record itself’

Editor's pick
The Guardian
5 November 2018
People & personal stories

'Nobody could make me laugh like you': Instagram memories of those lost to Aids

Editor's pick
The Guardian
5 November 2018
Injectable & long-acting HIV treatment

ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

Editor's pick
Poz
5 November 2018
Global health initiatives

Trump's State Department eyes ban on terms like 'sexual health'

Editor's pick
Politico
5 November 2018
PrEP science

PrEP Is Safe for Pregnant Women Who Want the HIV Prevention Drug, a New Study Finds

Editor's pick
The Body Pro
5 November 2018
Pregnancy and vertical transmission

Nigeria highest producer of HIV-infected babies

Editor's pick
Daily Post
5 November 2018
Ageing & HIV

Ageism And Sexuality

Editor's pick
Ageing Equal
5 November 2018
Heterosexual men

Reaching the men: who are the partners of the young women with HIV in South Africa?

News
5 November 2018
PrEP policies & guidelines

The NHS Refused To Give This Man The HIV Prevention Drug. He Got HIV.

Editor's pick
BuzzFeed
4 November 2018
People with limited treatment options

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows

News
2 November 2018
PrEP science

How safe is PrEP? Meta-analysis finds no increased risk of serious side-effects

News
2 November 2018
Child developmental issues

Hepatitis C increases the risk of premature delivery for pregnant women with HIV

News
2 November 2018
Undetectable viral load & treatment as prevention

aidsmapLIVE: AIDS 2018 special Video

November 2018
Cardiovascular disease

Cardiovascular Risk Unclear for HIV Patients on Dolutegravir

Editor's pick
Medscape (requires free registration)
1 November 2018
Starting treatment

Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA in Treatment-Naïve Adults with HIV-1

Editor's pick
Janssen press release
1 November 2018
Starting treatment

Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Editor's pick
Gilead press release
1 November 2018
The search for a cure

STEPS V: HIV cure community workshop in Glasgow

Editor's pick
EATG
1 November 2018
Mental & emotional health problems

Experts: Don't Overlook Mental Health in People Living With HIV

Editor's pick
Medpage Today
1 November 2018
HIV & criminal law

Man who infected two women with HIV and ‘took coward’s way out’ is jailed

Editor's pick
Metro
1 November 2018
Chemsex & recreational drug use

This Is How The Justice System Is Trying To Stop The Chemsex Crimewave

Editor's pick
BuzzFeed
1 November 2018
Starting treatment

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

News
1 November 2018
Bad science & bogus treatments

'No cure' for HIV in Zimbabwe says UN, following claims from local preacher

Editor's pick
UN News
1 November 2018
Vaginal rings & topical PrEP

Going local – prevention conference hears about rings, douches, and soluble suppositories

News
31 October 2018
Injectable & long-acting PrEP

Beyond Truvada – what is the future of PrEP?

News
31 October 2018